Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.